Payment overview · 2025
General Payments
$111.39
5 reported records · 3 companies
Healthcare provider profile · identity verified
Maury Hurst, MD
Allopathic & Osteopathic Physicians|Family Medicine · HIALEAH, FL · NPI 1629032248
Verified facts
What the public records show
CMS Open Payments records show Maury Hurst, MD received $111.39 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 47.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.00 | 47.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.46 | 37.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.93 | 15.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $111.39 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $53.00 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 83 |
| Temazepam | Temazepam | 189 | 34 |
| Alprazolam | Alprazolam | 184 | 36 |
| Omeprazole | Omeprazole | 159 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 145 | 47 |
| Meloxicam | Meloxicam | 145 | 41 |
| Losartan Potassium | Losartan Potassium | 138 | 47 |
| Clonazepam | Clonazepam | 127 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 113 | 35 |
| Azithromycin | Azithromycin | 104 | 77 |
| Montelukast Sodium | Montelukast Sodium | 97 | 36 |
| Gabapentin | Gabapentin | 96 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 23 |
| Ibuprofen | Ibuprofen | 92 | 33 |
| Famotidine | Famotidine | 89 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 86 | 39 |
| Memantine Hcl | Memantine Hcl | 86 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 78 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 78 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 71 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 18 |
| Carvedilol | Carvedilol | 67 | 21 |
| Lisinopril | Lisinopril | 63 | 29 |
| Furosemide | Furosemide | 61 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 17 |
| Glimepiride | Glimepiride | 60 | 18 |
| Ozempic | Semaglutide | 58 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 22 |
| Linzess | Linaclotide | 53 | 15 |
| Tramadol Hcl | Tramadol Hcl | 51 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 21 |
| Baclofen | Baclofen | 49 | 17 |
| Metformin Hcl | Metformin Hcl | 48 | 17 |
| Atenolol | Atenolol | 47 | 12 |
| Mounjaro | Tirzepatide | 45 | 12 |
| Eliquis | Apixaban | 44 | 11 |
| Ketoconazole | Ketoconazole | 43 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 42 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Folic Acid | Folic Acid | 40 | suppressed |
| Irbesartan | Irbesartan | 40 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 11 |
| Ciclopirox | Ciclopirox | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 13 |
| Nitroglycerin | Nitroglycerin | 36 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 36 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 11 |
| Ammonium Lactate | Ammonium Lactate | 31 | 17 |
| Hydrocortisone | Hydrocortisone | 31 | 13 |
| Simvastatin | Simvastatin | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | 12 |
| Methylprednisolone | Methylprednisolone | 28 | 19 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Jardiance | Empagliflozin | 27 | 11 |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Cilostazol | Cilostazol | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $111.39 · 5 records | ABBVIE INC. | JARDIANCE, LINZESS, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error